Clinical Trial

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Study acronym: AMPLIFY
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also assess safety, pharmacokinetics (PK) and changes in liver fat content related to patients diagnosed with MASH.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-19.
Trial Details
NCT Number NCT07491458
Lead Sponsor Rivus Pharmaceuticals, Inc.
Conditions MASH - Metabolic Dysfunction-Associated Steatohepatitis
Enrollment 180 participants
Start Date 2026-02-13
Primary Completion 2027-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-18